Familial Hypertriglyceridemia Treatments

Find Familial Hypertriglyceridemia Treatments

Generic Name

Fenofibrate

Brand Names

Lipofen, Tricor

FDA approval date: May 13, 2005

Classification: Peroxisome Proliferator Receptor alpha Agonist

Form: Tablet, Capsule

What is Lipofen (Fenofibrate)?

Antara is a peroxisome proliferator receptor alpha activator indicated as an adjunct to diet: to reduce elevated LDL-C, Total-C, triglycerides, and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia.

Approved To Treat

Top Global Experts

View All

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Tired of the same old research?

Check Latest Advances

Related Clinical Trials

A Phase II Study of Metronomic and Targeted Anti-angiogenesis Therapy for Children With Recurrent/Progressive Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors

Who is this study for: Patients with Medulloblastoma

Enrollment Status: Recruiting

Publish Date: February 23, 2026

Intervention Type: Drug

Study Drugs: Bevacizumab, Thalidomide, Celecoxib, Fenofibric Acid, Etoposide, Cyclophosphamide, Etoposide Phosphate, Cytarabine

Study Phase: Phase 2

Summary: Patients with with recurrent or progressive medulloblastoma, ependymoma, atypical teratoid rhabdoid tumor (ATRT), and CNS tumors of various histologies have a very poor prognosis whether treated with conventional chemotherapy, high-dose chemotherapy with stem cell rescue, irradiation or combinations of these modalities. Antiangiogenesis therapy has emerged as a new treatment option in solid malign...

An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Fenofibrate in Combination With Ursodeoxycholic Acid in Subjects With Primary Biliary Cholangitis (PBC)

Enrollment Status: Recruiting

Publish Date: January 08, 2026

Intervention Type: Drug

Study Phase: Phase 3

Summary: An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Fenofibrate in Combination with Ursodeoxycholic Acid in Subjects with Primary Biliary Cholangitis (PBC)

An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Fenofibrate in Combination With Ursodeoxycholic Acid in Subjects With Primary Biliary Cholangitis (PBC)

Enrollment Status: Recruiting

Publish Date: January 08, 2026

Intervention Type: Drug

Study Phase: Phase 3

Summary: An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Fenofibrate in Combination with Ursodeoxycholic Acid in Subjects with Primary Biliary Cholangitis (PBC)

View All Clinical Trials